Obesity Characteristics Are Poor Predictors of Genetic Mutations Associated with Obesity
Abstract
:1. Introduction
2. Materials and Methods
2.1. DNA Analysis
2.2. Statistical Analysis
3. Results
3.1. Heaviest Weight in Lifetime and Weight at Screening
3.2. Age of Hyperphagia, Onset of Heaviest Weight, and Onset of Obesity
3.3. Genetic Test Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Moradi-Lakeh, M.; Naghavi, M.; et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med. 2017, 377, 13–27. [Google Scholar] [CrossRef] [PubMed]
- Huvenne, H.; Dubern, B.; Clément, K.; Poitou, C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obes. Facts 2016, 9, 158–173. [Google Scholar] [CrossRef] [PubMed]
- Dai, H.; Alsalhe, T.A.; Chalghaf, N.; Riccò, M.; Bragazzi, N.L.; Wu, J. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: An analysis of the Global Burden of Disease Study. PLoS Med. 2020, 17, e1003198. [Google Scholar] [CrossRef]
- Okati-Aliabad, H.; Ansari-Moghaddam, A.; Kargar, S.; Jabbari, N. Prevalence of Obesity and Overweight among Adults in the Middle East Countries from 2000 to 2020: A Systematic Review and Meta-Analysis. J. Obes. 2022, 2022, 8074837. [Google Scholar] [CrossRef] [PubMed]
- Rivera, F.; Romero, C.; Jimenez-Fonseca, P.; Izquierdo-Manuel, M.; Salud, A.; Martinez, E.; Jorge, M.; Arrazubi, V.; Mendez, J.C.; Garcia-Alfonso, P.; et al. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother. Pharmacol. 2019, 83, 1175–1181. [Google Scholar] [CrossRef] [PubMed]
- Herrera, B.M.; Keildson, S.; Lindgren, C.M. Genetics and epigenetics of obesity. Maturitas 2011, 69, 41–49. [Google Scholar] [CrossRef] [PubMed]
- Yazdi, F.T.; Clee, S.M.; Meyre, D. Obesity genetics in mouse and human: Back and forth, and back again. PeerJ 2015, 3, e856. [Google Scholar] [CrossRef]
- Kühnen, P.; Krude, H.; Biebermann, H. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment. Trends Mol. Med. 2019, 25, 136–148. [Google Scholar] [CrossRef]
- Loos, R.J.F.; Yeo, G.S.H. The genetics of obesity: From discovery to biology. Nat. Rev. Genet. 2022, 23, 120–133. [Google Scholar] [CrossRef]
- Shi, Q.; Wang, Y.; Hao, Q.; Vandvik, P.O.; Guyatt, G.; Li, J.; Chen, Z.; Xu, S.; Shen, Y.; Ge, L.; et al. Pharmacotherapy for adults with overweight and obesity: A systematic review and network meta-analysis of randomised controlled trials. Lancet 2022, 399, 259–269. [Google Scholar] [CrossRef]
- Olateju, I.V.; Ogwu, D.; Owolabi, M.O.; Azode, U.; Osula, F.; Okeke, R.; Akabalu, I. Role of Behavioral Interventions in the Management of Obesity. Cureus 2021, 13, e18080. [Google Scholar] [CrossRef] [PubMed]
- Šket, R.; Kotnik, P.; Bizjan, B.J.; Kocen, V.; Mlinarič, M.; Tesovnik, T.; Debeljak, M.; Battelino, T.; Kovač, J. Heterozygous Genetic Variants in Autosomal Recessive Genes of the Leptin-Melanocortin Signalling Pathway Are Associated with the Development of Childhood Obesity. Front. Endocrinol. 2022, 13, 832911. [Google Scholar] [CrossRef] [PubMed]
- Roberts, K.J.; Ariza, A.J.; Selvaraj, K.; Quadri, M.; Mangarelli, C.; Neault, S.; Davis, E.E.; Binns, H.J. Testing for rare genetic causes of obesity: Findings and experiences from a pediatric weight management program. Int. J. Obes. 2022, 46, 1493–1501. [Google Scholar] [CrossRef]
- AbouHashem, N.; Zaied, R.E.; Al-Shafai, K.; Nofal, M.; Syed, N.; Al-Shafai, M. The Spectrum of Genetic Variants Associated with the Development of Monogenic Obesity in Qatar. Obes. Facts 2022, 15, 357–365. [Google Scholar] [CrossRef] [PubMed]
- Saeed, S.; Janjua, Q.M.; Haseeb, A.; Khanam, R.; Durand, E.; Vaillant, E.; Ning, L.; Badreddine, A.; Berberian, L.; Boissel, M.; et al. Rare Variant Analysis of Obesity-Associated Genes in Young Adults with Severe Obesity from a Consanguineous Population of Pakistan. Diabetes 2022, 71, 694–705. [Google Scholar] [CrossRef] [PubMed]
- Piché, M.E.; Tchernof, A.; Després, J.P. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ. Res. 2020, 126, 1477–1500. [Google Scholar] [CrossRef]
- Després, J.P. Body fat distribution and risk of cardiovascular disease: An update. Circulation 2012, 126, 1301–1313. [Google Scholar] [CrossRef]
- Smith, G.I.; Mittendorfer, B.; Klein, S. Metabolically healthy obesity: Facts and fantasies. J. Clin. Investig. 2019, 129, 3978–3989. [Google Scholar] [CrossRef]
- Després, J.P.; Lemieux, I.; Bergeron, J.; Pibarot, P.; Mathieu, P.; Larose, E.; Rodés-Cabau, J.; Bertrand, O.F.; Poirier, P. Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1039–1049. [Google Scholar] [CrossRef]
- Pi-Sunyer, F.X.; Becker, D.M.; Bouchard, C.; Carleton, R.A.; Colditz, G.A.; Dietz, W.H.; Foreyt, J.P.; Garrison, R.J.; Grundy, S.M.; Hansen, B.C.; et al. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report; National Institutes of Health: Bethesda, MD, USA, 1998; Volume 6, (Suppl. S2), pp. 51s–209s. [Google Scholar]
- Clément, K.; van den Akker, E.; Argente, J.; Bahm, A.; Chung, W.K.; Connors, H.; De Waele, K.; Farooqi, I.S.; Gonneau-Lejeune, J.; Gordon, G.; et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: Single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020, 8, 960–970. [Google Scholar] [CrossRef]
- Rhythm Pharmaceuticals, I. Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity. 2019. Available online: https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-launches-free-genetic-testing-program (accessed on 15 April 2023).
- Rhythm Pharmaceuticals, I. Uncovering Rare Obesity Full Gene Panel. Available online: www.rareobesity.com/resources (accessed on 1 August 2022).
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef] [PubMed]
- Albuquerque, D.; Stice, E.; Rodríguez-López, R.; Manco, L.; Nóbrega, C. Current review of genetics of human obesity: From molecular mechanisms to an evolutionary perspective. Mol. Genet. Genom. 2015, 290, 1191–1221. [Google Scholar] [CrossRef]
- Pigeyre, M.; Yazdi, F.T.; Kaur, Y.; Meyre, D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin. Sci. 2016, 130, 943–986. [Google Scholar] [CrossRef]
- Riggs, E.R.; Andersen, E.F.; Cherry, A.M.; Kantarci, S.; Kearney, H.; Patel, A.; Raca, G.; Ritter, D.I.; South, S.T.; Thorland, E.C.; et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet. Med. 2020, 22, 245–257. [Google Scholar] [CrossRef]
- Kearney, H.M.; Thorland, E.C.; Brown, K.K.; Quintero-Rivera, F.; South, S.T. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet. Med. 2011, 13, 680–685. [Google Scholar] [CrossRef]
- Rehm, H.L.; Bale, S.J.; Bayrak-Toydemir, P.; Berg, J.S.; Brown, K.K.; Deignan, J.L.; Friez, M.J.; Funke, B.H.; Hegde, M.R.; Lyon, E. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 2013, 15, 733–747. [Google Scholar] [CrossRef]
- Van der Sande, M.A.; Walraven, G.E.; Milligan, P.J.; Banya, W.A.; Ceesay, S.M.; Nyan, O.A.; McAdam, K.P. Family history: An opportunity for early interventions and improved control of hypertension, obesity and diabetes. Bull. World Health Organ. 2001, 79, 321–328. [Google Scholar]
- Heymsfield, S.B.; Avena, N.M.; Baier, L.; Brantley, P.; Bray, G.A.; Burnett, L.C.; Butler, M.G.; Driscoll, D.J.; Egli, D.; Elmquist, J.; et al. Hyperphagia: Current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity 2014, 22 (Suppl. S1), S1–S17. [Google Scholar] [CrossRef]
- Yeo, G.S.H.; Chao, D.H.M.; Siegert, A.M.; Koerperich, Z.M.; Ericson, M.D.; Simonds, S.E.; Larson, C.M.; Luquet, S.; Clarke, I.; Sharma, S.; et al. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy. Mol. Metab. 2021, 48, 101206. [Google Scholar] [CrossRef]
- Nead, K.T.; Li, A.; Wehner, M.R.; Neupane, B.; Gustafsson, S.; Butterworth, A.; Engert, J.C.; Davis, A.D.; Hegele, R.A.; Miller, R.; et al. Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: A systematic review and meta-analysis with evidence from up to 331 175 individuals. Hum. Mol. Genet. 2015, 24, 3582–3594. [Google Scholar] [CrossRef]
- Baldini, G.; Phelan, K.D. The melanocortin pathway and control of appetite-progress and therapeutic implications. J. Endocrinol. 2019, 241, R1–R33. [Google Scholar] [CrossRef] [PubMed]
- Harno, E.; Gali Ramamoorthy, T.; Coll, A.P.; White, A. POMC: The Physiological Power of Hormone Processing. Physiol. Rev. 2018, 98, 2381–2430. [Google Scholar] [CrossRef] [PubMed]
- Courbage, S.; Poitou, C.; Le Beyec-Le Bihan, J.; Karsenty, A.; Lemale, J.; Pelloux, V.; Lacorte, J.M.; Carel, J.C.; Lecomte, N.; Storey, C.; et al. Implication of Heterozygous Variants in Genes of the Leptin-Melanocortin Pathway in Severe Obesity. J. Clin. Endocrinol. Metab. 2021, 106, 2991–3006. [Google Scholar] [CrossRef] [PubMed]
- Farooqi, S.; O’Rahilly, S. Genetics of obesity in humans. Endocr. Rev. 2006, 27, 710–718. [Google Scholar] [CrossRef] [PubMed]
- Wabitsch, M.; Fehnel, S.; Mallya, U.G.; Sluga-O’Callaghan, M.; Richardson, D.; Price, M.; Kühnen, P. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies. Adv. Ther. 2022, 39, 1772–1783. [Google Scholar] [CrossRef]
- Haws, R.; Brady, S.; Davis, E.; Fletty, K.; Yuan, G.; Gordon, G.; Stewart, M.; Yanovski, J. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes. Metab. 2020, 22, 2133–2140. [Google Scholar] [CrossRef]
- Kühnen, P.; Clément, K.; Wiegand, S.; Blankenstein, O.; Gottesdiener, K.; Martini, L.L.; Mai, K.; Blume-Peytavi, U.; Grüters, A.; Krude, H. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N. Engl. J. Med. 2016, 375, 240–246. [Google Scholar] [CrossRef]
- Segal, M. Genetic Testing for Obesity: Implications and Challenges. Curr. Obes. Rep. 2017, 6, 93–100. [Google Scholar] [CrossRef]
- Folon, L.; Baron, M.; Toussaint, B.; Vaillant, E.; Boissel, M.; Scherrer, V.; Loiselle, H.; Leloire, A.; Badreddine, A.; Balkau, B.; et al. Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: A case-control study. Lancet Diabetes Endocrinol. 2023, 11, 182–190. [Google Scholar] [CrossRef]
- Akbari, P.; Gilani, A.; Sosina, O.; Kosmicki, J.A.; Khrimian, L.; Fang, Y.Y.; Persaud, T.; Garcia, V.; Sun, D.; Li, A.; et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science 2021, 373, eabf8683. [Google Scholar] [CrossRef]
Characteristics/Indicator | Categories | n | Median */Mean | Percentage/IQR */SEM |
---|---|---|---|---|
Gender | Male | 89 | 37.4% | |
Female | 149 | 62.6% | ||
Age (years) | 238 | 51 * | 18 * | |
Height (cm) | 238 | 169.2 | 0.6 | |
Heaviest lifetime weight (kg) | 238 | 140.2 | 1.8 | |
Weight at screening (kg) | 238 | 119 | 1.9 | |
Heaviest lifetime BMI (kg/m2) | 238 | 48.9 | 0.5 | |
BMI at screening (kg/m2) | 238 | 41.3 | 0.6 | |
Onset of hyperphagia (years) | 238 | 7.1 | 0.4 | |
Age of heaviest weight (years) | 238 | 42.5 | 0.8 | |
Onset of obesity (years) | 238 | 12.6 | 0.8 | |
History of childhood obesity | Yes | 171 | 71.8% | |
No | 67 | 28.2% | ||
History of hyperphagia | Yes | 194 | 81.5% | |
No | 44 | 18.5% | ||
History of failure to thrive before the age of 2 | Yes | 13 | 5.5% | |
No | 222 | 93.3% | ||
Unknown | 3 | 1.3% | ||
History of thyroid disease | Yes | 37 | 15.5% | |
No | 199 | 83.6%% | ||
Unknown | 2 | 0.8% | ||
History of using anti-obesity medication | Yes | 151 | 63.4% | |
No | 87 | 36.6% | ||
History of bariatric surgery | Yes | 83 | 34.9% | |
No | 155 | 65.1% | ||
Family history of obesity | Yes | 187 | 78.6% | |
No | 42 | 17.6% | ||
Unknown | 9 | 3.8% | ||
Family history of obesity (Father) | 97 | 40.8% | ||
Family history of obesity (Mother) | 113 | 47.5% | ||
Family history of obesity (Siblings) | 129 | 54.2% |
Outcome | Categories | n | % |
---|---|---|---|
Genetic test result | Negative | 131 | 55 |
Positive | 107 | 45 | |
Number of subjects with gene mutations detected | 1-gene mutation | 81 | 34 |
2-gene mutations | 19 | 8 | |
3-gene mutations | 6 | 2.5 | |
4-gene mutations | 1 | 0.4 | |
Gene category a | Category 1 | 83 | 34.9 |
Category 2 | 24 | 10.1 | |
Category 3 | 131 | 55 |
Variable | Genetic Result | Mean/Frequency | SEM or Percentage | p Value |
---|---|---|---|---|
Heaviest lifetime BMI (kg/m2) | Negative | 49.4 | 0.7 | 0.4 |
Positive | 48.4 | 0.8 | ||
Heaviest lifetime weight (kg) | Negative | 140.9 | 2.3 | 0.7 |
Positive | 139.4 | 2.7 | ||
Onset of obesity (years) | Negative | 11.5 | 0.9 | 0.1 |
Positive | 13.9 | 1.3 | ||
Age of hyperphagia (years) | Negative | 6.9 | 0.4 | 0.4 |
Positive | 7.5 | 0.6 | ||
Positive history of childhood obesity | Negative | 99 | 41.6% | 0.2 |
Positive | 72 | 30.3% | ||
Positive history of hyperphagia during childhood | Negative | 104 | 43.7% | 0.4 |
Positive | 90 | 37.8% | ||
Positive family history of obesity | Negative | 101 | 42.4% | 0.7 |
Positive | 86 | 36.1% |
Variable | Gene Category | Mean/Frequency | SEM or Percentage | p Value |
---|---|---|---|---|
Heaviest lifetime BMI (kg/m2) | Category 1 | 48.1 | 0.99 | 0.6 |
Category 2 | 49.3 | 1.4 | ||
Category 3 | 49.4 | 0.7 | ||
Heaviest lifetime weight (kg) | Category 1 | 138.7 | 3.1 | 0.8 |
Category 2 | 141.9 | 5.2 | ||
Category 3 | 140.9 | 2.3 | ||
Onset of obesity (years) | Category 1 | 13.9 | 1.5 | 0.3 |
Category 2 | 14 | 2.7 | ||
Category 3 | 11.5 | 0.9 | ||
Age of hyperphagia (years) | Category 1 | 7.9 | 0.8 | 0.3 |
Category 2 | 6.4 | 0.8 | ||
Category 3 | 6.9 | 0.4 | ||
Positive history of childhood obesity | Category 1 | 57/83 | 23.9% | 0.3 |
Category 2 | 15/24 | 6.3% | ||
Category 3 | 99/131 | 41.6% | ||
Positive history of hyperphagia during childhood | Category 1 | 68/83 | 28.6% | 0.4 |
Category 2 | 22/24 | 9.2% | ||
Category 3 | 104/131 | 43.7% | ||
Positive family history of obesity | Category 1 | 67/83 | 28.2% | 0.8 |
Category 2 | 19/24 | 7.9% | ||
Category 3 | 101/131 | 42.4% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Al-Humadi, A.W.; Alabduljabbar, K.; Alsaqaaby, M.S.; Talaee, H.; le Roux, C.W. Obesity Characteristics Are Poor Predictors of Genetic Mutations Associated with Obesity. J. Clin. Med. 2023, 12, 6396. https://doi.org/10.3390/jcm12196396
Al-Humadi AW, Alabduljabbar K, Alsaqaaby MS, Talaee H, le Roux CW. Obesity Characteristics Are Poor Predictors of Genetic Mutations Associated with Obesity. Journal of Clinical Medicine. 2023; 12(19):6396. https://doi.org/10.3390/jcm12196396
Chicago/Turabian StyleAl-Humadi, Ahmed W., Khaled Alabduljabbar, Moath S. Alsaqaaby, Hani Talaee, and Carel W. le Roux. 2023. "Obesity Characteristics Are Poor Predictors of Genetic Mutations Associated with Obesity" Journal of Clinical Medicine 12, no. 19: 6396. https://doi.org/10.3390/jcm12196396